Clinical Cancer Research
Published Online First
March 11, 2016; doi: 10.1158/1078-0432.CCR-16-021
Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine
Soumaya Karaki1, Helene PERE2, Cecile Badoual3, and Eric Tartour4,*
Author Affiliations
1Immunology, INSERM U970
2VIROLOGY, HEGP
3Immunology, INSERRM U970
4Immunology, Université Paris Descartes, Sorbonne Paris Cité; INSERM U970, Paris-Cardiovascular Research Center (PARCC); AP-HP, Hôpital Européen Georges Pompidou
Abstract
A pool of long synthetic peptides derived from HPV16 proteins induce objective partial or complete histological regression of lesions in more than 50% of patients with high-grade vulvar (VuVIN3) and vaginal intraepithelial neoplasia (VaIN3). The intensity of T cell response induced by the vaccine was correlated with clinical response.